(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -11.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.95%.
Nektar Therapeutics's revenue in 2026 is $62,600,000.On average, 10 Wall Street analysts forecast NKTR's revenue for 2026 to be $868,321,410, with the lowest NKTR revenue forecast at $478,434,173, and the highest NKTR revenue forecast at $1,162,806,594. On average, 9 Wall Street analysts forecast NKTR's revenue for 2027 to be $719,990,543, with the lowest NKTR revenue forecast at $161,471,533, and the highest NKTR revenue forecast at $1,226,536,792.
In 2028, NKTR is forecast to generate $979,406,827 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $2,420,038,843.